David Hastings
Director of Finance/CFO presso ARBUTUS BIOPHARMA CORPORATION
Patrimonio netto: 503 399 $ in data 31/03/2024
Profilo
David C.
Hastings is an Independent Director at SCYNEXIS, Inc. since 2015, an Independent Director at Entasis Therapeutics, Inc. since 2018, an Independent Director at Entasis Therapeutics Holdings, Inc. since 2018, and the Chief Financial & Accounting Officer at Arbutus Biopharma Corp.
since 2019.
He previously worked as a Finance Director at Sumitomo Pharma America, Inc. from 1994 to 1997, an Independent Non-Executive Director at Vascular Biogenics Ltd.
from 2018 to 2023, the Chief Financial Officer & Executive Vice President at Incyte Corp.
from 2012 to 2014, the Chief Financial Officer, Treasurer & VP at ArQule, Inc. from 2000 to 2003, a Senior Manager at PricewaterhouseCoopers LLP in 1994, the Vice President & Controller at Genzyme Corp.
from 1997 to 2000, and the Treasurer, Chief Financial & Accounting Officer at Unilife Corp.
from 2016 to 2017.
He obtained his undergraduate degree from the University of Vermont.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 02/02/2024 | 181 907 ( 0.10% ) | 469 320 $ | 31/03/2024 | |
SCYNEXIS, INC.
0.06% | 15/06/2023 | 23 183 ( 0.06% ) | 34 079 $ | 31/03/2024 |
Posizioni attive di David Hastings
| Società | Posizione | Inizio |
|---|---|---|
| SCYNEXIS, INC. | Director/Board Member | 24/09/2015 |
| ARBUTUS BIOPHARMA CORPORATION | Director of Finance/CFO | 11/06/2018 |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Director/Board Member | 01/04/2018 |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Director/Board Member | 01/04/2018 |
Precedenti posizioni note di David Hastings
| Società | Posizione | Fine |
|---|---|---|
| NOTABLE LABS, LTD. | Director/Board Member | 16/10/2023 |
| UNILIFE CORP | Director of Finance/CFO | 05/06/2017 |
| INCYTE CORPORATION | Director of Finance/CFO | 31/10/2014 |
| ARQULE, INC. | Director of Finance/CFO | 01/09/2003 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Comptroller/Controller/Auditor | 01/02/2000 |
Formazione di David Hastings
| University of Vermont | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| SCYNEXIS, INC. | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| Aziende private | 8 |
|---|---|
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Unilife Corp.
 Unilife Corp. Medical SpecialtiesHealth Technology Unilife Corp. designs, develops, manufactures and supplies injectable drug delivery systems. The company builds long-term collaborations with pharmaceutical and biotechnology companies seeking to utilize its devices to enable or enhance the clinical development, regulatory approval and lifecycle management of injectable therapies. The company was founded by Alan D. Shortall in 2001 and is headquartered in York, PA. | Health Technology |
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Borsa valori
- Insiders
- David Hastings
